Targretin is a drug owned by Valeant Pharmaceuticals Luxembourg Sarl. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 29, 2018. Details of Targretin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(8 years ago) |
Expired
|
| US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(9 years ago) |
Expired
|
FDA has granted several exclusivities to Targretin. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Targretin, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Targretin.
Exclusivity Information
Targretin holds 1 exclusivities. All of its exclusivities have expired in 2018. Details of Targretin's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
US patents provide insights into the exclusivity only within the United States, but Targretin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Targretin's family patents as well as insights into ongoing legal events on those patents.
Targretin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Targretin's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 29, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Targretin Generic API suppliers:
Bexarotene is the generic name for the brand Targretin. 9 different companies have already filed for the generic of Targretin, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Targretin's generic
About Targretin
Targretin is a drug owned by Valeant Pharmaceuticals Luxembourg Sarl. It is used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma. Targretin uses Bexarotene as an active ingredient. Targretin was launched by Valeant Luxembourg in 1999.
Approval Date:
Targretin was approved by FDA for market use on 29 December, 1999.
Active Ingredient:
Targretin uses Bexarotene as the active ingredient. Check out other Drugs and Companies using Bexarotene ingredient
Treatment:
Targretin is used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma.
Dosage:
Targretin is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75MG | CAPSULE | Prescription | ORAL |
Targretin is a drug owned by Bausch Health Ireland Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 29, 2018. Details of Targretin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(8 years ago) |
Expired
|
| US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(9 years ago) |
Expired
|
FDA has granted several exclusivities to Targretin. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Targretin, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Targretin.
Exclusivity Information
Targretin holds 1 exclusivities. All of its exclusivities have expired in 2018. Details of Targretin's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
US patents provide insights into the exclusivity only within the United States, but Targretin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Targretin's family patents as well as insights into ongoing legal events on those patents.
Targretin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Targretin's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 29, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Targretin Generic API suppliers:
Bexarotene is the generic name for the brand Targretin. 9 different companies have already filed for the generic of Targretin, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Targretin's generic
About Targretin
Targretin is a drug owned by Bausch Health Ireland Ltd. It is used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma. Targretin uses Bexarotene as an active ingredient. Targretin was launched by Bausch in 2000.
Approval Date:
Targretin was approved by FDA for market use on 28 June, 2000.
Active Ingredient:
Targretin uses Bexarotene as the active ingredient. Check out other Drugs and Companies using Bexarotene ingredient
Treatment:
Targretin is used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma.
Dosage:
Targretin is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | GEL | Prescription | TOPICAL |